

Airway Clearance Devices (for Ohio Only)

Policy Number: CS054OH.D
Effective Date: June 1, 2026

[Instructions for Use](#)

Table of Contents	Page
Application	1
Coverage Rationale	1
Medical Records Documentation Used for Reviews	1
Applicable Codes	2
Clinical Evidence	2
U.S. Food and Drug Administration	4
References	4
Policy History/Revision Information	5
Instructions for Use	5

Related Policy

- [Durable Medical Equipment, Orthotics, Medical Supplies, and Repairs/Replacements \(for Ohio Only\)](#)

Application

This Medical Policy only applies to the state of Ohio. Any requests for services that are stated as unproven or services for which there is a coverage or quantity limit will be evaluated for medical necessity using Ohio Administrative Code 5160-1-01.

Coverage Rationale

Note: For general coverage and payment policies for durable medical equipment (DME), prosthesis, orthotic devices, medical/surgical supplies, and supplier services, refer to the [Ohio Administrative Code, Rule 5160-10-01: Durable Medical Equipment, Prostheses, Orthoses, and Supplies \(DMEPOS\): General Provisions](#).

For medical necessity clinical coverage criteria of high-frequency chest wall oscillation (HFCWO) devices, refer to the [Ohio Administrative Code, Rule 5160-10-08: DMEPOS: High-Frequency Chest Wall Oscillation \(HFCWO\) Devices](#).

For medical necessity clinical coverage criteria for an intrapulmonary percussive ventilation system, refer to the InterQual® CP: Durable Medical Equipment, Airway or Secretion Clearance Devices.

[Click here to view the InterQual® criteria.](#)

Combination continuous positive expiratory pressure, continuous high-frequency oscillation, and nebulized medication therapy devices for oscillation and lung expansion are considered unproven and not medically necessary.

Coverage Limitations and Exclusions

For coverage limitations and exclusions, refer to the [Ohio Administrative Code, Rule 5160-10-01: Durable Medical Equipment, Prostheses, Orthoses, and Supplies \(DMEPOS\): General Provisions](#) and the [Ohio Administrative Code, Rule 5160-10-02: DMEPOS: Repair](#).

Medical Records Documentation Used for Reviews

Benefit coverage for health services is determined by the federal, state, or contractual requirements, and applicable laws that may require coverage for a specific service. Medical records documentation may be required to assess whether the member meets the clinical criteria for coverage but does not guarantee coverage of the services requested.

The patient's medical record must contain documentation that fully supports the medical necessity for the requested services. This documentation includes, but is not limited to, relevant medical history, physical examination, and results of pertinent diagnostic tests or procedures. Documentation supporting the medical necessity should be legible, maintained in the patient's medical record, and must be made available upon request.

Applicable Codes

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by federal, state, or contractual requirements and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

Note: Coverage will remain consistent with the ODM Fee for Service Fee Schedule.

HCPCS Code	Description
A7021	Supplies and accessories for lung expansion airway clearance, continuous high frequency oscillation, and nebulization device (e.g., handset, nebulizer kit, biofilter)
A7025	High frequency chest wall oscillation system vest, replacement for use with patient- owned equipment, each
A7026	High frequency chest wall oscillation system hose, replacement for use with patient- owned equipment, each
E0469	Lung expansion airway clearance, continuous high frequency oscillation, and nebulization device
E0481	Intrapulmonary percussive ventilation system and related accessories
E0483	High frequency chest wall oscillation system, with full anterior and/or posterior thoracic region receiving simultaneous external oscillation, includes all accessories and supplies, each

Clinical Evidence

Combination Continuous Positive Expiratory Pressure, Continuous High-Frequency Oscillation, and Nebulized Medication Therapy Devices for Oscillation and Lung Expansion

Due to insufficient quality evidence or consistency of findings, combination continuous PEP, continuous high-frequency oscillation, and nebulized medication therapy devices for oscillation and lung expansion (OLE) are considered unproven and not medically necessary.

Main and Rand (2023) conducted a systematic review and meta-analysis to evaluate the effectiveness (in terms of respiratory function, respiratory exacerbations, and exercise capacity) and acceptability (in terms of individual preference, adherence, and quality of life) of conventional CPT (CCPT) for people with cystic fibrosis compared with alternative ACTs. The authors included randomized or quasirandomized controlled trials (including crossover design) that lasted at least 7 days and compared CCPT with alternative ACTs in people with cystic fibrosis. The primary outcomes were (1) pulmonary function tests and (2) number of respiratory exacerbations per year. The secondary outcomes were (1) quality of life, (2) adherence to therapy, (3) cost-benefit analysis, (4) objective change in exercise capacity, (5) additional lung function tests, (6) ventilation scanning, (7) blood oxygen levels, (8) nutritional status, (9) mortality, (10) mucus transport rate, and (11) mucus wet or dry weight. Outcomes were reported as short term (7-20 days), medium term (more than 20 days to up to 1 year), and long term (over 1 year). A total of 21 (778 individuals) studies comprising seven short-term, eight medium-term, and six long-term studies were included. Studies were conducted in the U.S. (10), Canada (five), Australia (two), the UK (two), Denmark (one), and Italy (one), with a median of 23 individuals per study (range, 13-166 individuals). Individuals' ages ranged from newborns to 45 years; most studies only recruited children and young people. Sixteen studies reported the sex of individuals (375 male; 296 female). Most studies compared modifications of CCPT with a single comparator, but two studies compared three interventions, and another compared four interventions. The interventions varied in the duration of treatments, times per day, and periods of comparison, making meta-analysis challenging. All evidence was very low certainty. Overall, 19 studies reported the primary outcomes of FEV₁ and FVC and found no difference in change from baseline in FEV₁ percent predicted or rate of decline between groups for either measure. Most studies suggested equivalence between CCPT and alternative ACTs, including PEP, extrapulmonary mechanical percussion, ACBT, O-PEP devices, autogenic drainage, and exercise. Where single studies suggested superiority of one ACT, these findings were not corroborated in similar studies; pooled data generally concluded that the

effects of CCPT were comparable to those of alternative ACTs. Regarding CCPT vs PEP, the authors are uncertain whether CCPT improves lung function or has an impact on the number of respiratory exacerbations per year compared with PEP (both very low-certainty evidence). There were no analyzable data for secondary outcomes, but many studies provided favorable narrative reports on the independence achieved with PEP mask therapy. Regarding CCPT vs extrapulmonary mechanical percussion, the authors are uncertain whether CCPT improves lung function compared with extrapulmonary mechanical percussions (very low-certainty evidence). The annual rate of decline in average forced expiratory flow between 25% and 75% of FVC (FEF₂₅₋₇₅) was greater with high-frequency chest compression than CCPT in medium- to long-term studies, but there was no difference in any other outcome. Regarding CCPT vs ACBT, the authors are uncertain whether CCPT improves lung function compared with ACBT (very low-certainty evidence). The annual decline in FEF₂₅₋₇₅ was worse in individuals who were using the forced expiration technique component of ACBT only [mean difference (MD), 6.00; 95% CI, 0.55-11.45; one study, 63 individuals; very low-certainty evidence]. One short-term study reported that directed coughing was as effective as CCPT for all lung function outcomes but with no analyzable data. One study found no difference in hospital admissions and days in hospital for exacerbations. Regarding CCPT vs O-PEP, the authors are uncertain whether CCPT improves lung function compared with O-PEP devices (Flutter device and IPV); however, only one study provided analyzable data (very low-certainty evidence). No study reported data for the number of exacerbations. There was no difference in results for the number of days in hospital for an exacerbation, number of hospital admissions, and number of days of intravenous antibiotics; this was also true for other secondary outcomes. Regarding CCPT vs autogenic drainage, the authors are uncertain whether CCPT improves lung function compared with autogenic drainage (very low-certainty evidence). No studies reported the number of exacerbations per year; however, one study reported more hospital admissions for exacerbations in the CCPT group (MD, 0.24; 95% CI, 0.06-0.42; 33 individuals). One study provided a narrative report of a preference for autogenic drainage. Regarding CCPT vs exercise, the authors are uncertain whether CCPT improves lung function compared with exercise (very low-certainty evidence). An analysis of original data from one study demonstrated a higher FEV₁ percent predicted (MD, 7.05; 95% CI, 3.15-10.95; $p = 0.0004$), FVC (MD, 7.83; 95% CI, 2.48-13.18; $p = 0.004$), and FEF₂₅₋₇₅ (MD, 7.05; 95% CI, 3.15-10.95; $p = 0.0004$) in the CCPT group; however, the study reported no difference between groups (likely because the original analysis accounted for baseline differences). The authors concluded that they are uncertain whether CCPT has a more positive impact on respiratory function, respiratory exacerbations, individual preference, adherence, quality of life, exercise capacity, and other outcomes compared with alternative ACTs, as the certainty of the evidence is very low. There was no advantage in respiratory function of CCPT over alternative ACTs, but this may reflect insufficient evidence rather than real equivalence. Narrative reports indicated that individuals prefer self-administered ACTs. This review is limited by a paucity of well-designed, adequately powered, long-term studies. This review cannot yet recommend any single ACT above others; physiotherapists and people with cystic fibrosis may wish to try different ACTs until they find an ACT that suits them best.

Morrison and Milroy (2020) conducted a systematic review and meta-analysis to identify whether oscillatory devices, oral or chest wall, are effective for mucociliary clearance and whether they are equivalent or superior to other forms of airway clearance in the successful management of secretions in people with cystic fibrosis. Search criteria included RCTs and controlled clinical studies of oscillating devices compared with any other form of physiotherapy in people with cystic fibrosis. Single-treatment interventions (therapy technique used only once in the comparison) were excluded. Two authors independently applied the inclusion criteria to publications, assessed the quality of the included studies, and assessed the evidence using GRADE (Grading of Recommendations Assessment, Development, and Evaluation). The searches identified 82 studies (330 references); 39 studies (total of 1,114 individuals) met the inclusion criteria. Studies varied in duration from up to 1 week to 1 year; 20 of the studies were crossover in design. The studies also varied in type of intervention and the outcomes measured; data were not published in sufficient detail in most of these studies, so meta-analysis was limited. Few studies were considered to have a low risk of bias in any domain. It is not possible to blind individuals and clinicians to physiotherapy interventions, but 13 studies did blind the outcome assessors. The quality of the evidence across all comparisons ranged from low to very low. FEV₁ was the most frequently measured outcome, and while many of the studies reported an improvement in those people using a vibrating device compared with before the study, there were few differences when comparing the different devices to each other or to other ACTs. One study identified an increase in frequency of exacerbations requiring antibiotics while using HFCWO compared with PEP (low-quality evidence). There were some small but significant changes in secondary outcome variables such as sputum volume or weight but not wholly in favor of oscillating devices, and due to the low- or very low-quality evidence, it is not clear whether these were due to the particular intervention. Individuals' satisfaction was reported in 13 studies but again with low- or very low-quality evidence and not consistently in favor of an oscillating device, as some individuals preferred breathing techniques or techniques used prior to the study interventions. The results for the remaining outcome measures were not examined or reported in sufficient detail to provide any high-level evidence. The authors concluded that there was no clear evidence that oscillation was a more or less effective intervention overall than other forms of physiotherapy; furthermore, there was no evidence that one device was superior to another. The findings from one study that showed an increase in the frequency of exacerbations requiring antibiotics while using an oscillating device compared with PEP may have significant resource implications. More adequately powered, long-term RCTs are necessary, and the outcomes

measured should include frequency of exacerbations, individual preference, adherence to therapy, and general satisfaction with treatment. Increased adherence to therapy may then lead to improvements in other parameters, such as exercise tolerance and respiratory function. Additional evidence is needed to evaluate whether oscillating devices combined with other forms of airway clearance are efficacious in people with cystic fibrosis. There may also be a requirement to consider the cost implication of devices over other forms of equally advantageous ACTs. Using the GRADE method to assess the quality of the evidence, we judged this to be low or very low quality, which suggests that further research is very likely to have an impact on confidence in any estimate of effect that is generated by future interventions.

Huynh et al. (2019) conducted a multicenter, nonrandomized, prospective study to examine the impact of OLE therapy using continuous high-frequency oscillation and continuous PEP on postoperative pulmonary complications (PPCs) in high-risk participants. In stage I, Current Procedural Terminology and International Classification of Diseases codes were queried for participants (n = 210) who were undergoing thoracic, upper abdominal, or aortic open procedures at three institutions from December 2014 to April 2016. Participants were selected randomly. Age, comorbidities, American Society of Anesthesiologists Physical Status Classification scores, and PPC rates were determined. In stage II, 209 participants were enrolled prospectively from October 2016 to July 2017 using the same criteria. Stage II participants received OLE treatment and standard respiratory care. The PPCs rate [prolonged ventilation, high-level respiratory support, pneumonia, and intensive care unit (ICU) readmission] was compared. The authors also compared ICU length of stay, hospital length of stay, and mortality using t tests and analysis of covariance. Data are mean \pm SD. There were 419 participants. Stage II participants were older (61.1 \pm 13.7 years vs. 57.4 \pm 15.5 years; $p < 0.05$) and had higher American Society of Anesthesiologists scores. Treatment with OLE decreased PPCs from 22.9% (stage I) to 15.8% (stage II) ($p < 0.01$ adjusted for age, American Society of Anesthesiologists score, and operation time). Similarly, OLE treatment reduced ventilator time (23.7 \pm 107.5 hours to 8.5 \pm 27.5 hours; $p < 0.05$) and hospital length of stay (8.4 \pm 7.9 days to 6.8 \pm 5.0 days; $p < 0.05$). No differences in ICU length of stay, pneumonia, or mortality were observed. The authors concluded that aggressive treatment with OLE reduces PPCs and resource use in high-risk surgical individuals. Well designed, adequately powered, prospective, controlled clinical trials in combination OLE treatment are needed to further describe safety and clinical efficacy.

U.S. Food and Drug Administration (FDA)

This section is to be used for informational purposes only. FDA approval alone is not a basis for coverage.

High-Frequency Chest Wall Compression Devices

High-frequency chest wall compression devices are designed to promote airway clearance and improve bronchial drainage. They are indicated when external chest manipulation is the physician's treatment of choice to enhance mucus transport. Refer to the following website for more information (use product code BYI):

<http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm>. (Accessed October 14, 2025)

References

Huynh TT, Liesching TN, Cereda M, et al. Efficacy of oscillation and lung expansion in reducing postoperative pulmonary complication. *J Am Coll Surg*. 2019 Nov;229(5):458-466.e1.

Main E, Rand S. Conventional chest physiotherapy compared to other airway clearance techniques for cystic fibrosis. *Cochrane Database Syst Rev*. 2023 May 5;5(5):CD002011.

Morrison L, Milroy S. Oscillating devices for airway clearance in people with cystic fibrosis. *Cochrane Database Syst Rev*. 2020 Apr 30;4(4):CD006842.

Ohio Administrative Code/5160/Chapter 5160-10-01. Durable medical equipment, prostheses, orthoses, and supplies (DMEPOS): general provisions. Available at: <https://codes.ohio.gov/ohio-administrative-code/rule-5160-10-02>. Accessed January 7, 2026.

Ohio Administrative Code/5160/Chapter 5160-10-08 | DMEPOS: high-frequency chest wall oscillation (HFCWO) devices. Available at: <https://codes.ohio.gov/ohio-administrative-code/rule-5160-10-08>. Accessed January 7, 2026.

Ohio Administrative Code/5160/Chapter 5160-1-01. Medicaid medical necessity: definitions and principles. Available at: <https://codes.ohio.gov/ohio-administrative-code/rule-5160-1-01>. Accessed January 7, 2026.

Policy History/Revision Information

Date	Summary of Changes
06/01/2026	<p data-bbox="337 201 1044 233">Medical Records Documentation Used for Reviews</p> <ul data-bbox="337 233 1498 569" style="list-style-type: none"><li data-bbox="337 233 716 264">● Added language to indicate:<ul data-bbox="386 264 1498 569" style="list-style-type: none"><li data-bbox="386 264 1438 327">○ Benefit coverage for health services is determined by the federal, state, or contractual requirements, and applicable laws that may require coverage for a specific service<li data-bbox="386 327 1498 390">○ Medical records documentation may be required to assess whether the member meets the clinical criteria for coverage but does not guarantee coverage of the service requested<li data-bbox="386 390 1466 453">○ The patient's medical record must contain documentation that fully supports the medical necessity for the requested services<li data-bbox="386 453 1398 516">○ This documentation includes but is not limited to relevant medical history, physical examination, and results of pertinent diagnostic tests or procedures<li data-bbox="386 516 1430 569">○ Documentation supporting the medical necessity should be legible, maintained in the patient's medical record, and must be made available upon request <p data-bbox="337 569 586 600">Applicable Codes</p> <ul data-bbox="337 600 1406 663" style="list-style-type: none"><li data-bbox="337 600 1406 663">● Added notation to indicate coverage will remain consistent with the Ohio Department of Medicaid (ODM) Fee for Service Fee Schedule <p data-bbox="337 663 662 695">Supporting Information</p> <ul data-bbox="337 695 1235 768" style="list-style-type: none"><li data-bbox="337 695 1235 726">● Updated <i>Clinical Evidence</i> section to reflect the most current information<li data-bbox="337 726 922 768">● Archived previous policy version CS054OH.C

Instructions for Use

This Medical Policy provides assistance in interpreting UnitedHealthcare standard benefit plans. When deciding coverage, the federal, state (Ohio Administrative Code [OAC]) or contractual requirements for benefit plan coverage must be referenced as the terms of the federal, state (OAC) or contractual requirements for benefit plan coverage may differ from the standard benefit plan. In the event of a conflict, the federal, state (OAC) or contractual requirements for benefit plan coverage govern. Before using this policy, check the federal, state (OAC) or contractual requirements for benefit plan coverage. UnitedHealthcare reserves the right to modify its Policies and Guidelines as necessary. This Medical Policy is provided for informational purposes. It does not constitute medical advice.

UnitedHealthcare uses InterQual® for the primary medical/surgical criteria, and the American Society of Addiction Medicine (ASAM) for substance use, in administering health benefits. If InterQual® does not have applicable criteria, UnitedHealthcare may also use UnitedHealthcare Medical Policies, Coverage Determination Guidelines, and/or Utilization Review Guidelines that have been approved by the Ohio Department for Medicaid Services. The UnitedHealthcare Medical Policies, Coverage Determination Guidelines, and Utilization Review Guidelines are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.